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ABSTRACT 
BACKGROUND AND PURPOSE: Although targeted by radiotherapy, recurrence in glioblastoma occurs 
mainly periresectional due to tumour infiltration. An increase in ADC is shown posttreatment in the 
large high T2 area, however, until now ADC has not been investigated for the more relevant directly 
periresectional area. 
METHODS: Histogram analysis was used to assess periresectional ADC values in glioblastoma patients 
postradiotherapy versus preradiotherapy. Periresectional ADC values of 0-5 mm with 5 mm 
increment up to 20-25 mm were extracted and compared with a two-way repeated measurement 
ANOVA.   
RESULTS: Mean ADC values were significantly higher postradiotherapy directly adjacent to the 
resection area (0-5 mm) compared to preradiotherapy (p=0.017). The 0-5 mm ADC values were also 
higher than those in 5-10, 10-15 and 15-20 mm regions (p<0.05). Regional standard deviations of 
ADC values were higher postradiotherapy compared to preradiotherapy for the 0-5 up to 15-20 mm 
region, inclusive (p<0.05). Cox regression analysis however showed no survival benefits for the 0-5 
mm area increase in ADC postradiotherapy. 
CONCLUSIONS: Increased ADC values representing a decrease in infiltrative tumour load was 
demonstrated in a limited direct periresectional area. This adds to previous studies looking at the 
larger high T2 area showing ADC response in relation to survival. 
  
INTRODUCTION 
Brain tumours are an expanding research area with a significant population burden. Glioblastomas 
are the most prevalent primary brain tumours, and one of the leading cancers in terms of years of life 
lost [1]. These tumours tend to recur despite maximal surgical resection of the contrast enhancing 
region of the tumour. This is followed by radiotherapy targeted at the surroundings of the resection 
area and combined with temozolomide chemotherapy [2]. Despite this, recurrence is still inevitable, 
happening even in all patients with a total resection of the contrast enhancing tumour and 
subsequent chemoradiotherapy. Recurrence occurs within or directly adjacent to the resection area 
in up to 90% [3], likely due to the infiltrative nature of the tumour spreading beyond the contrast 
enhancing region [4].  
 
Recent studies demonstrated the potential of apparent diffusion coefficients (ADC) values for 
evaluating tumour recurrence. In a group of 20 brain tumour patients of which 7 had a glioblastoma, 
early changes in functional diffusion maps could be used to predict treatment response in patients 
treated with radiotherapy, chemotherapy or a combination of both [5]. Functional diffusion maps 
also  identified response patterns in patients with glioblastomas treated with boron neutron capture 
therapy [6]. This was further supported in a rat glioblastoma model showing a correlation between 
histological decline in tumour cell density and increase in ADC days after the start of chemotherapy 
[7,8], which also correlated for spatial heterogeneity of ADC response and tumour cell density [8]. 
Correlation between cell density and ADC has also been demonstrated in patients with untreated 
glioblastomas [9].  
 
Studies that assess ADC changes after radiotherapy are scarce. Studies in glioblastoma patients, of 
whom less than 50% received a total resection, showed an increase of ADC values postradiotherapy 
in comparison with preradiotherapy values in the residual contrast enhancing tumour and in the 
surrounding  T2-hyperintens area [10,11]. This was also related to survival in both studies [10,11]. 
However, as advanced surgical techniques such as neuronavigation and intraoperative 5-
aminolevulinic acid (5-ALA) fluorescence guidance [12] allow resection of more than 90% of the 
contrast enhancing tumour volume, assessment of ADC values in this contrast enhancing region is of 
little practical relevance. Similarly, the large area of T2-hyperintense tumour is composed of both 
infiltrating tumour and vasogenic oedema. It thus can extend far beyond the original contrast 
enhancement and thus also beyond the periresection area where tumour recurrence is most likely to 
occur [3]. 
 
This prompted us to assess the ADC values specifically in a smaller periresection area using pre- and 
postradiotherapy MRI scans in patients with a glioblastoma treated with surgical resection and 




Patient inclusion criteria 
Patients with a newly diagnosed cerebral glioblastoma were included in this study. Patients were 
collected consecutively from 2010-2014. We included all patients with MRI follow up data from a 
initial cohort designed for a preoperative imaging study. Exclusion criteria were previous cranial 
surgery, previous cerebral radiotherapy, a known other primary tumour or follow-up outside our 
hospitals. Patients with a glioblastoma crossing the midline were not excluded. We included 14 
patients (see Table 1 for general characteristics). Tumour location was defined as previously 
described [13]. All patients were on a stable dexamethasone dose and had a Karnofsky performance 
status ≥70. Surgical resection was performed using neuronavigation (StealthStation, Medtronic) and 
5-ALA fluorescence guidance with the aim of maximal resection. Surgery was followed by standard 
concomitant chemoradiotherapy and adjuvant chemotherapy [2] starting 4 weeks after surgery. 
Radiotherapy consisted of 60 Gy following the EORTC protocol with 60Gy in 30 fractions (2Gy 
fractions given once daily for five days a week over a six week period) [14]. Radiotherapy was 
delivered to the resection margin with a total margin of 3 cm in all patients. Follow-up MRI scans 
were collected directly after surgery, as well as pre- and postradiotherapy. The postoperative MRI 
was performed <72 hours after the operation. Direct preradiotherapy MRI was on average 21 days 
after the operation (range 14-32), while postradiotherapy MRI was on average 87 days (2.9 months) 
thereafter (range 77-96 days; 2.6-3.2 months). As preradiotherapy scans were missing in 3 patients, 
data concerning this time point was based on 11 patients, while other analyses were done on all 14 
patients. Progression free survival and overall survival data were established based on medical 
records. Progression free survival was defined according to the RANO criteria [15].  
The study was approved by the local Institutional Review Board and informed written consent was 
obtained from all patients. 
 
Data acquisition 
MRI scans were acquired on a 1.5 T GE Optima, 1.5 or 3.0 T GE Signa or 3.0 T GE Discovery (General 
Electric Company, Little Chalfont, United Kingdom) with a standard head coil. Imaging included a T1-
weighted anatomical sequence after the intravenous injection of 9 ml gadolinium (Gadovist, Bayer 
Schering Pharma, Berlin, Germany). This was performed as a 2D T1-weighted sequence (TR/TE 400-
784/11-20 ms, flip angle 90-160°, FOV 220-240 x 220-240 mm; 20-84 slices; 0-1 mm slice gap; voxel 
size 0.43-0.86 x 0.43-0.86 x 2-6 mm) or a 2D T1 inversion recovery sequence (TR/TE 2508-2590/12-42 
ms, inversion time 780-920 ms; flip angle 90-110°, FOV 220 × 220 mm; 20-22 slices; 1-3.5 mm slice 
gap; voxel size of 0.43 x 0.43 x 6 mm).  
DWI data was acquired using a single-shot echo-planar sequence (TR/TE 6000-12500/64-108 ms; flip 
angle 90°; FOV 220-300 x 220-300 mm; 52-66 slices; 0-4 mm slice gap; voxel size 0.86-1.2 x 0.86-1.2 x 




ADC images were coregistered to the T1-weighted post contrast images of the same time point using 
tools from the FMRIB Software Library (FSL) version 5.0.0 (www.fmrib.ox.ac.uk/fsl). The brain images 
were automatically extracted [16] and manually corrected. A linear transformation of the brain 
images was done using the FLIRT function, resulting in ADC images coregistered to post contrast T1 
images. 
 
ADC data were normalised to the contralateral normal appearing white matter. Contralateral MRI 
abnormality in for instance a glioblastoma crossing the midline were avoided in this process. The 
resection cavity was identified with an automatic segmentation using the FSL FAST function [17] and 
manually corrected. The resection cavity was dilated to create a 3D region of 0-5, 5-10, 10-15, 15-20 
and 20-25 mm around the resection (Figure 1) as these are the most common areas for tumour 
recurrence [3,18] and thus most relevant for treatment evaluation using ADC values. The resection 
cavity itself, ventricles and areas outside of the brain were excluded.  
 
Statistical analysis 
In general, direct postoperative ADC values were similar to direct preradiotherapy. We therefore 
used preradiotherapy ADC values as primary baseline for comparison to postradiotherapy images. In 
addition, we compared the direct postoperative images with the postradiotherapy images as a 
preradiotherapy ADC is not acquired as standard in all clinical practices. Histogram analysis was used 
testing the mean, standard deviation, skewness and kurtosis. Skewness indicates the asymmetry of 
the distribution, while kurtosis represents the width and height of a distribution. Both represent the 
heterogeneity of a distribution, but in a different way, meaning that both can be normal of abnormal 
independent from each other. A two-way within subject analysis of variance was conducted to assess 
ADC values at different distances from the resection cavity using five factors starting with 0-5 mm 
from the resection cavity with 5 mm increments up to 20-25 mm from the resection cavity. Two time 
points were entered as factor (before and after radiotherapy). A similar analysis of variance was 
conducted for directly postoperative versus postradiotherapy. Mauchly’s test of sphericity was used 
to test the sphericity for the main effect of distance and interaction between time and distance. As 
the assumption of sphericity was violated in all cases, we used Greenhouse-Geisser corrected output 
for all analyses of variance. Post-hoc comparisons used a paired t-test or Wilcoxon-signed rank test 
depending on the normality. The normality was tested using the Shapiro-Wilk test.  
We further investigated the predictive value of the increase of the postradiotherapy ADC of the 0-5 
mm area for the progression free survival and overall survival, first using a univariate Cox regression 
model. Secondly, a multivariate Cox regression model was use correcting for age and O6-
methylguanin-DNA-methyltransferase (MGMT) methylation status. The Cox proportional hazard 
assumption test were performed for all Cox regression models showing no violation of this 
assumption.  
Two-sided p-values were used throughout. All statistical tests were performed using SPSS version 22 




Group mean, standard deviations, skewness and kurtosis of the patients mean of the periresection 
voxels are demonstrated (Figure 2).  
 
Mean ADC values at different distances from the resection cavity showed a significant interaction 
between time and distance (Figure 2A) (F(1.8,18)=5.4, p=0.018). There was no significant main effect 
of time (F(1,10)=1.9, p=0.195) or distance (F(1.2,12)=2.5, p=0.062). Post-hoc comparison showed a 
statistically significant increase in the ADC value directly adjacent (0-5 mm) to the resection cavity 
postradiotherapy in comparison to preradiotherapy (t(10)=-2.8, p=0.017). Postoperative values 
increased 0.19, from 1.29 to 1.48. Furthermore, for the postradiotherapy data, the 0-5 mm region 
differed significantly from the 5-10 (t(13)=2.8, p=0.014), 10-15 (t(13)=3.0, p=0.010), 15-20 (t(13)=3.2, 
p=0.007) and 20-25 mm region (t(13)=3.3 p=0.006).The 5-10 mm region also was significantly 
different to the 20-25 mm region (t(13)=2.3, p=0.038). 
The mean postoperative ADC values compared to postradiotherapy showed no significant interaction 
between time and distance (F(1.4,18)=2.1, p=0.158). There was no main effect of time (F(1,13)=1.1, 
p=0.311), but there was for distance (F(1.3,16)=5.6, p=0.024). Post-hoc comparison only revealed a 
marginally statistical significant result for the 0-5 mm region(t(13)=-2.1, p=0.051).  
 
To demonstrate the heterogeneity of the voxels within the region of interest the standard deviations 
were compared (Figure 2B). There was no significant interaction between time and distance 
(F(1.5,15)=0.95, p=0.384)  comparing postradiotherapy with preradiotherapy. There was a significant 
main effect of time (F(1,10)=13.5, p=0.004). There was no main effect of distance (F(1.5,15)=0.52, 
p=0.556). Post-hoc comparison for the time showed a statistically significant difference for the 0-5 
mm region, which demonstrated a higher standard deviation postradiotherapy compared to 
preradiotherapy (Z=2.1, p=0.033). The same was true comparing the postradiotherapy with the 
preradiotherapy for the 5-10 (t(10)=-3.1, p=0.011), 10-15 (t(13)=-4.3, p=0.002) and 15-20 mm region 
(t(13)=-3.2, p=0.010), but it was only marginally significant for the 20-25 mm region (t(13)=-2.2, 
p=0.051). 
Postoperative compared to postradiotherapy standard deviations showed no significant interaction 
between time and distance (F(1.5,19.9)=0.64, p=0.499). There was a significant main effect of time 
(F(1,13)=5.6, p=0.034), but not for distance (F(1.2,16)=0.88, p=0.386). Post-hoc comparison for the 
time showed that the 5-10 mm region was higher postradiotherapy than postoperative (Z=2.3. 
p=0.022). Other regions demonstrated no statistically significant differences.  
 
Analysis of skewness (Figure 2C) representing the asymmetry of the histogram demonstrated no 
significant interaction comparing postradiotherapy with preradiotherapy (F(2.1,21)=0.93, p=0.414). 
No significant main effect of time was demonstrated (F(1,10)=2.5, p =0.148). A significant main effect 
of distance was present (F(1.3,13)=9.7, p=0.006). Post-hoc testing showed a significantly lower 
skewness for the 0-5 mm region in comparison to the 5-10 (t(13)=-2.3, p=0.037), 10-15 (t(13)=-3.9, 
p=0.002), 15-20 (t(13)=-4.1, p=0.001) and 20-25 mm region (t(13)=-4.1, p=0.001) in the 
postradiotherapy data. The 5-10 mm region was also significantly lower compared to the 10-15 (t()=-
2.5, p=0.027), 15-20 (t()=-2.8, p=0.015) and 20-25 mm region (t()=-2.4, p=0.034) postradiotherapy. 
There were no significant differences within the preradiotherapy time point although values were 
similar, but slightly less different than postradiotherapy. 
Comparing the skewness of the postoperative with the postradiotherapy images showed similar 
results. There was no significant interaction between distance and time (F(2.5,33)=2.4, p=0.093) or 
main effect for time (F(1,13)=0.11, p=0.750). A significant main effect was found for distance 
(F(2.1,27)=8.9, p<0.001). Post-hoc tests of postradiotherapy results are already described. 
Postoperative values were comparable, but there was only a statistically significant difference for the 
0-5 mm region in comparison to the 20-25 mm region (t()=-2.3, p=0.038). 
 
Kurtosis analysis (Figure 2D) indicating the height and sharpness of the histogram for the 
postradiotherapy and preradiotherapy time point showed no significant interaction (F(1.5,15)=0.084, 
p=0.869) and no main effect of time (F(1,10)=3.2, p=0.106). A significant main effect was shown for 
distance (F(1.7,17)=4.8, p=0.026). Post-hoc testing within the postradiotherapy data revealed a 
flatter and wider distribution for the 0-5 mm region compared to the 10-15 (t(13)=-2.6, p=0.021), 15-
20 (t(13)=-3.0, p=0.011) and 20-25 mm region (t(13)=-2.9, p=0.013). The 5-10 mm region was also 
lower than the 10-15 (t(13)=-2.9, p=0.011), 15-20 (t(13)=-3.1, p=0.008) and 20-25 mm region (t(13)=-
3.3, p=0.006). A similar distribution was seen preradiotherapy, but without statistically significant 
differences. 
Kurtosis of postoperative compared to postradiotherapy showed no interaction between time and 
distance (F(1.8,23)=0.39. p=0.657). No main effect for time was demonstrated (F(1,13)=0.66, 
p=0.430). A significant main effect for distance was shown (F(2.6, 34)=11.4, p<0.001). The 
postoperative distribution resembled the preradiotherapy and postradiotherapy distribution. Post-
hoc testing within the postoperative moment demonstrated a statistically significant lower kurtosis 
for the 0-5 mm region in comparison to the 5-10 (Z=2.2, p=0.026), 10-15 (Z=2.5, p=0.011), 15-20 
(Z=2.5, p=0.011) and 20-25 mm region (Z=2.4, p=0.016).  
 
Survival analysis 
The increase in ADC value postradiotherapy in comparison to preradiotherapy for the 0-5 mm area 
did not predict an increase in progression free survival (HR=0.414, p=0.711) or overall survival 
(HR=0.224, p=0.692). This did not change significantly after adjusting for age and MGMT status with a 




This is the first study to selectively analyse periresectional change of ADC values, as previous 
research has only looked at the large high T2 area [10,11]. We demonstrated that mean ADC values 
were most likely to increase in the area directly adjacent to the resection cavity (0-5 mm), while 
moving further away, the changes quickly became less pronounced. The highest infiltrating tumour 
load is also to be expected in the 0-5 mm area. The demonstrated heterogeneity of the skewness and 
kurtosis postradiotherapy might possible be also explained by this higher a priori tumour load as well 
as heterogeneity in tumour response most pronounced in this area were most tumour is present.  
 
Although a histological correlation has not been performed in this study, previous research has 
validated the correlation between ADC values and viable tumour cells in rats [7,9] and humans [9] 
with glioblastoma. Furthermore, ADC changes preceded contrast enhancement in tumour recurrence 
indicating the recurrence of tumour cells before these cells induce a disruption of the blood-brain 
barrier [19]. Observed increase in ADC values after treatment therefore indicate a reduction of 
tumour cellularity due to radiotherapy.  
 
Reduction of tumour cell density in the direct peritumoural area is of specific interest. Radiotherapy 
currently targets the resection site and the adjacent region, which was also the case for the patients 
in our study in combination with chemotherapy. However, this is insufficient as recurrence is still 
inevitable and occurs in about 90% of the patients within or directly adjacent to the resection area 
[3]. Low ADC indicative of a high amount of tumour cells in recurrent glioblastoma seen in 95% within 
the 60 Gy isodose line is associated with poorer outcome [20]. This might be due to the variable 
treatment response of glioblastoma cells [8], which is also suggested by our increased standard 
deviation postradiotherapy. Even more focus on localised therapy thus seems logical and therapy like 
Carmustine wafers is of interest [21]. In these cases, however, one would expect to see a survival 
benefit in patients with ADC response, which we were unable to demonstrate. Our absent 
correlation with survival might be due to the small group size and could also be partially influenced 
by treatment given after finishing chemoradiotherapy and tumour progression. However, others 
have clearly demonstrated a correlation between an increase in ADC values after treatment and 
outcome. Studies in glioblastoma patients with mixed nonsurgical treatment showed that ADC in the 
high T2 region differs in patients with progression of the T2 and patients with stable T2 disease [22]. 
The same holds for the contrast enhancing area [10,23] and FLAIR area [10]. However, others 
demonstrate no correlation with ADC values after treatment but instead demonstrated a correlation 
of midtreatment ADC values with survival [24]. The correlation with survival is demonstrated for 
preradiotherapy ADC values in the FLAIR region correlating with progression free survival and overall 
survival in patients with glioblastoma, most of them with a subtotal resection [25]. Preradiotherapy 
ADC values also might be more accurate than direct postoperative values due to minor areas with 
lower ADC values directly postoperative caused by minor ischemic changes. As our ADC 
postoperative is slightly higher in the 0-5 mm area in comparison to preradiotherapy ischemic 
changes is unlikely to have influenced postoperative values. Ischemic changes would not be a 
confounding factor in the preradiotherapy scans as they were all acquired >14 days (mean 21 days) 
after the operation, at which time any restricted diffusion secondary to ischaemic changes would 
normalise.  
 
One of the main future applications of ADC response would be the early stratification of patients into 
responders and nonresponders. This would provide more time for secondary therapeutic 
interventions, which increases their chance of being effective. It also could prevent unnecessary 
ineffective, possible toxic and costly treatment in non-responders. Anatomical MRI using the increase 
in tumour size is incapable of demonstrating early changes. As a result, research has focussed on 
apparent diffusion coefficients calculated from diffusion weighted MRI. We are the first to show the 
increase of ADC specific to the area adjacent to the resection as result of chemoradiotherapy after 
the end of radiotherapy. Others have shown that ADC is also capable of demonstrating an early 
change in a population with mixed brain tumour [5] and in a rat model with glioblastoma [7,8]. ADC 
is thus a potential early imaging biomarker of treatment response. Further research should focus on 
periresectional ADC values in glioblastoma patients early in the current standard treatment, but also 
in studies investigating new localised therapies.  
 
In such research, voxel-based ADC response parameters are likely to be more accurate than a single 
posttreatment measurement and parametric response maps have been shown to outperform a 
single posttreatment measurement for the prediction of outcome at 3 months and 1 year in treated 
glioblastoma patients [26]. A parametric response map, however, needs 3D volumetric acquisitions 
pre- and posttreatment. This is often not acquired as standard in clinical practice. Our more 
simplified histogram calculations using 2D MRI data therefore has wider applicability. We also used 
MRI scanners of different manufactures and field strengths. To overcome the known variation that 
can result from this [27], we successfully used ADC values normalised to the contralateral normal 
appearing white matter. This is also an advantage for the applicability of histogram ADC response 
calculations in clinical practice, in which one also have to deal with different MRI scanners and 
different ADC settings with most commonly used 2D acquisitions.  
 
Nevertheless, voxel-based ADC analysis in glioblastoma patients are in line with our histogram 
results, although previous studies have not looked specifically at the periresection area. A 
comparable patient population of which most also received surgery showed higher ADC values 
posttreatment [24]. Others have shown similar results in patients without surgery treated with 
radiotherapy or chemotherapy [5] and boron neutron capture therapy [6] at the location of the 
primary tumour. An increase of ADC values postradiotherapy in comparison with preradiotherapy 
values in the contrast enhancing tumour and in the area with high T2 signal was also been 
demonstrated [10,11].   
 
A few limitation can be identified in our study. The relatively small sample size and absence of a 
correlation with survival in our study has been discussed above. Another limitation is the lack of 
histological confirmation. However, a higher viable tumour load has been confirmed to correspond 
with lower ADC values in glioblastoma patients previously [9] making that we can interpreted our 




In conclusion, we calculate ADC response in the periresection area and showed an increase in ADC 
postradiotherapy. This has not been demonstrated previously in the periresectional region, but is in 
line with studies looking at the large areas with high T2 showing a higher ADC posttreatment in 
correlation with a better outcome. 
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FIGURE 1 – Periresectional regions on ADC  
Periresectional regions of interest are displayed for the preradiotherapy ADC map of a representative 
patients. Regions are 0-5 mm with 5 mm increments to 20-25, inclusive.   
FIGURE 2 – Normalised ADC in the periresection areas 
Histogram analysis of normalised apparent diffusion coefficient (ADC) values are displayed. The 
periresectional area of the postOP, preRT and postRT is divided in 5 regions starting from 0-5 mm 
periresectional with 5 mm increment up to 20-25 mm. Group means and standard deviation are 
shown for the subjects mean (A), standard deviation (B), skewness (C) and kurtosis (D). Significant 
post-hoc tests (p<0.05) are displayed if the main effect or interaction was significant (*). 
Abbreviations: postOP=postoperative; preRT=preradiotherapy; postRT=postradiotherapy. 
